Assessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise

Simply Wall St.04-04 14:27

AdvertisementWhy the CE Mark and equity raise matter for 4DMedical The trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624948036?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-04-04 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624948036","market":"hk","top_or_hot":-1,"title":"Assessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy the CE Mark and equity raise matter for 4DMedical The trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing 4DMedical (ASX:4DX) Valuation After CE Mark Approval And A$83 Million Equity Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-04 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy the CE Mark and equity raise matter for 4DMedical The trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CE","symbol_name":"塞拉尼斯","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval","article_id":"2624948036","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-ce-mark-approval","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624948036","pubTimestamp":1775284045,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why the CE Mark and equity raise matter for 4DMedical\nThe trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the European Union and highlights a new phase for the company’s respiratory imaging ambitions.\nThis certification arrives alongside an A$83.0 million follow-on equity offering at A$5.90 per share, suggesting 4DMedical is pairing European market access with fresh capital to support CT:VQ deployment and broader...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CE":"塞拉尼斯","BK4109":"特种化学制品","BK7094":"医疗保健技术","BK4215":"住宅房地产投资信托","BK4588":"碎股","4DX.AU":"4DMEDICAL LTD","BK4585":"ETF&股票定投概念","EQR":"资产住宅公司"},"translate_title":"在CE标志批准和8300万美元股权融资后评估4DMedical(ASX：4DX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"4DX.AU":1.5,"CE":1.5},"content_text":"AdvertisementWhy the CE Mark and equity raise matter for 4DMedical The trigger for 4DMedical (ASX:4DX) is the CE Mark approval for its CT:VQ imaging technology, which opens commercial use across the European Union and highlights a new phase for the company’s respiratory imaging ambitions. This certification arrives alongside an A$83.0 million follow-on equity offering at A$5.90 per share, suggesting 4DMedical is pairing European market access with fresh capital to support CT:VQ deployment and broader product development. See our latest analysis for 4DMedical. 4DMedical’s share price has cooled in the very short term, with a 1 day share price return of 5.21% and 7 day share price return of 10.19%. This follows a strong 30 day share price return of 39.26% and year to date share price return of 24.23%, while the multi year total shareholder return has been very large, reflecting shifting expectations around CT:VQ’s commercial potential and the recent A$83.0 million equity raise. If this kind of medical imaging story has your attention, it can be useful to see what else is moving in related areas through our healthcare AI stock screener, starting with 9 healthcare AI stocks So with CE Mark approval secured, fresh A$83.0 million in equity raised at A$5.90 per share and a recent A$5.64 close, is 4DMedical still offering upside, or is the market already pricing in future growth? Most Popular Narrative: 49.2% Undervalued The leading narrative on 4DMedical pegs fair value at A$11.11 per share, compared with the recent A$5.64 close, framing the CE Mark and equity raise in a much bigger context.  4DMedical is the first non-invasive, contrast free imaging technology for lung scanning. The new CT:VQ lung scanner is the first technology of its kind and is rapidly being adopted by clinics and big name KOLs in America. 4DMedical's goals for 2026 are to rapidly scale and expand across major AMCs, building more credibility and reputation among other clinics to help expand their technology. Partnership with Philips promised a $10 million USD minimum order commitment contract over the 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedical's CT:VQ technology as an official product on their catalog in North America. Backing by PME (Pro Medicus) with a $10 million AUD strategic investment, a hybrid type of debt / equity investment in 4DX. An interest rate of 12.5% p.a. that 4DX (4DMedical) needs to repay PME (Pro Medicus) with a maturity of 2 years. US Veteran Care is a big focus for 4DMedical and Philips, with Philips building a relationship in the Department of Veterans Affairs for the past 45 years, which can help 4DMedical navigate into the industry to provide for US VA health care faster. A major $150 million capital raise institutional placement with the help of Bell Potter Securities in mid January 2026 (at 3.8% dilution to public shareholders) is expected to help rapidly accelerate the scaling and expansion of new CT:VQ across America. Pro forma cash position is now over $200 million on the balance sheet for 4DMedical, giving them cash runway for a long time and the ability to market and scale with more budget. Earnings in 4DMedical are not expanding rapidly yet, as many of the new contracts and clinics adopted are mainly for KOL purposes. However, after the discounted price for the universities and clinics to use their technology, they will be reimbursed per scan, as well as their 90% profit margins on SaaS products.  Read the complete narrative. Curious how this view gets to a valuation almost double the current price? The narrative leans on aggressive revenue scaling, high margins and a premium future earnings multiple, all tied to adoption of CT:VQ and related software. The numbers behind those assumptions are where the real story sits. Result: Fair Value of A$11.11 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this relies heavily on ambitious market share goals and high margin assumptions. Any slower uptake or pricing pressure could quickly weaken that undervalued case. Find out about the key risks to this 4DMedical narrative. Next Steps If this mix of optimism and concern around 4DMedical leaves you on the fence, move quickly to weigh both sides for yourself and see the 1 key reward and 5 important warning signs. Looking for more investment ideas? If 4DMedical has sharpened your interest, do not stop here, the next opportunity often shows up where investors are not yet looking.  Target companies that the market may be overlooking by scanning screener containing 14 high quality undiscovered gems for strong fundamentals hiding behind quieter share price moves. Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (19 results) and focus on businesses with healthier financial foundations. Put income at the centre of your plan by checking the 7 dividend fortresses and see which companies currently offer higher yields with staying power.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624948036","isCrawlerRequest":true}